Literature DB >> 8148309

[Establishment and characterization of a CA125-producing human ovarian clear cell carcinoma cell line].

H Sasa1, K Ishii, J Hirata, Y Kikuchi, I Nagata, T Kawai, A Senoo, M Sugita, T Sugishita, Y Tenjin.   

Abstract

A human ovarian cancer cell line designated "KK" was established from ascites of a patient with ovarian clear cell carcinoma. This cell line was grown for more than 2 years and over 140 passages in medium RPMI1640 containing 10% FCS. Doubling time of this cell line at passage 70 was approximately 4 days and saturation density was 1.1 x 10(5)/cm2. Plating efficiency was approximately 23%. Chromosome analysis revealed aneuploidy with a model number of 67. PAS-positive substances were present in the cytoplasm. CA125 and SLX were detected in both the original tumor and the cultured cells. This cell line is less sensitive to cisplatin than KF cells and IC50 was 0.95 microM.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8148309

Source DB:  PubMed          Journal:  Hum Cell        ISSN： 0914-7470            Impact factor:   4.174


  5 in total

1.  JAK2/STAT3 pathway as a therapeutic target in ovarian cancers.

Authors:  Tomoyuki Yoshikawa; Morikazu Miyamoto; Tadashi Aoyama; Hiroaki Soyama; Tomoko Goto; Junko Hirata; Ayako Suzuki; Isao Nagaoka; Hitoshi Tsuda; Kenichi Furuya; Masashi Takano
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

2.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

3.  X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.

Authors:  M Miyamoto; M Takano; K Iwaya; N Shinomiya; M Kato; T Aoyama; N Sasaki; T Goto; A Suzuki; J Hitrata; K Furuya
Journal:  Br J Cancer       Date:  2014-05-22       Impact factor: 7.640

4.  Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.

Authors:  Morikazu Miyamoto; Masashi Takano; Tadashi Aoyama; Hiroaki Soyama; Tomoyuki Yoshikawa; Hitoshi Tsuda; Kenichi Furuya
Journal:  J Gynecol Oncol       Date:  2017-02-13       Impact factor: 4.401

5.  HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.

Authors:  Masaki Fujimura; Noriyuki Katsumata; Hiroshi Tsuda; Naoko Uchi; Satomi Miyazaki; Takao Hidaka; Masatoshi Sakai; Shigeru Saito
Journal:  Jpn J Cancer Res       Date:  2002-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.